Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forma To Rev Its Discovery Engine For Deubiquitination

This article was originally published in The Pink Sheet Daily

Executive Summary

In a new collaboration with Cancer Research Technology, drug-discovery firm Forma Therapeutics adds another area of cancer biology – and another unusual deal structure – to its panoply of partnerships.

You may also be interested in...



Celgene Returns To Forma’s Door, This Time With Option To Buy

The big biotech signed an expansive collaboration with the drug discovery company spanning multiple targets and numerous therapeutic areas. Celgene agreed to pay $225 million upfront and could eventually buy the company.

Deals of the Week: Is Botox On The Block?

A pair of setbacks have sent Allergan’s stock price south, but will a buyer take advantage and buy it in a mega-deal? Also, Amgen and Servier team up in a CV deal, Forma pursues an asset-focused strategy in tandem with Cancer Research Technology, and Immunocore reveals an antibody deal with GSK.

With Celgene Deal, Forma Makes First Foray Into Clinical Development

Forma Therapeutics has signed its largest and most ambitious oncology drug-discovery and development collaboration to date, in the exciting but early-stage area of protein homeostasis. Its new partner Celgene is no stranger to making big bets on promising cancer companies.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS076077

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel